Cerebrospinal fluid histamine levels are decreased in patients with narcolepsy and excessive daytime sleepiness of other origin

被引:40
|
作者
Bassetti, Claudio L. [1 ]
Baumann, Christian R. [1 ]
Dauvilliers, Yves [2 ]
Croyal, Michael [3 ]
Robert, Philippe [3 ]
Schwartz, Jean-Charles [3 ]
机构
[1] Osped Civico, Neuroctr EOC So Switzerland, Lugano, Switzerland
[2] CHU Hop Gui de Chauliac, INSERM U888, Montpellier, France
[3] Bioprojet Biotech, St Gregoire, France
关键词
CSF; EDS; histamine; hypersomnia; hypocretin; narcolpesy; orexin; HYPOCRETIN OREXIN DEFICIENCY; CSF HISTAMINE; PEPTIDES; NEURONS;
D O I
10.1111/j.1365-2869.2010.00819.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
P>Histaminergic neurons of the hypothalamic tuberomammillary nucleus constitute a major wake-promoting system. In animals, cerebrospinal fluid (CSF) histamine levels are increased during wakefulness and after sleep deprivation and decreased during sleep. An involvement of the histamine system in human disorders has not, to our knowledge, been reported. We measured hypocretin-1 and histamine levels in the lumbar CSF of 28 patients with and without excessive daytime sleepiness (EDS) as assessed by the Epworth Sleepiness Scale (ESS). There were 10 patients with EDS (ESS > 10, mean ESS = 14). Diagnoses included narcolepsy (n = 4), idiopathic hypersomnia (n = 2), sleep apnoea (n = 2) and multiple sclerosis (n = 2). Three patients were treated with stimulants. Their mean CSF histamine was 258 +/- 159 PM. There were 18 patients without EDS (ESS < 9, mean ESS = 5). No patients were treated with stimulants. Their mean CSF histamine was significantly higher (624 +/- 481 PM, P = 0.007). There was a significant inverse correlation (r = -0.48, P = 0.02) between ESS and both CSF histamine and hypocretin-1 levels. These observations suggest that narcolepsy and EDS of other origin are associated in humans with lower CSF histamine levels and therefore with a reduced activity of the wake-promoting histaminergic neuronal system.
引用
收藏
页码:620 / 623
页数:4
相关论文
共 50 条
  • [1] Histamine in Narcolepsy and Excessive Daytime Sleepiness
    Nishino, Seiji
    NARCOLEPSY: PATHOPHYSIOLOGY, DIAGNOSIS, AND TREATMENT, 2011, : 47 - 60
  • [2] Decreased hypocretin-1 (Orexin-A) levels in the cerebrospinal fluid of patients with myotonic dystrophy and excessive daytime sleepiness
    Martinez-Rodríguez, JE
    Lin, L
    Iranzo, A
    Genis, D
    Marti, MJ
    Santamaria, J
    Mignot, E
    SLEEP, 2003, 26 (03): : 287 - 290
  • [3] Treatment of Excessive Daytime Sleepiness in Patients with Narcolepsy
    Porez-Carbonell, Laura
    CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2019, 21 (11)
  • [4] Narcolepsy and excessive daytime sleepiness
    Zeman, A
    Britton, T
    Douglas, N
    Hansen, A
    Hicks, J
    Howard, R
    Meredith, A
    Smith, I
    Stores, G
    Wilson, S
    Zaiwalla, Z
    BMJ-BRITISH MEDICAL JOURNAL, 2004, 329 (7468): : 724 - 728C
  • [5] Treating Excessive Daytime Sleepiness in Patients With Narcolepsy
    Roth, Thomas
    JOURNAL OF CLINICAL PSYCHIATRY, 2020, 81 (05)
  • [6] Treatment of Excessive Daytime Sleepiness in Patients with Narcolepsy
    Laura Pérez-Carbonell
    Current Treatment Options in Neurology, 2019, 21
  • [7] Narcolepsy and excessive daytime sleepiness
    Reading, P
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2006, 77 (07): : 893 - 893
  • [8] Recognizing and Treating Excessive Daytime Sleepiness in Patients With Narcolepsy
    Roth, Thomas
    Winkelman, John W.
    JOURNAL OF CLINICAL PSYCHIATRY, 2020, 81 (06)
  • [9] Correction to: Treatment of Excessive Daytime Sleepiness in Patients with Narcolepsy
    Laura Pérez-Carbonell
    Current Treatment Options in Neurology, 2019, 21
  • [10] SAMELISANT, HISTAMINE 3 RECEPTOR AGONIST FOR THE POTENTIAL TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY
    Nirogi, Ramakrishna
    Ravula, Jyothsna
    Jayarajan, Pradeep
    Goyal, Vinod Kumar
    Jetta, Satish
    Shinde, Anil
    Benade, Vijay
    SLEEP, 2023, 46 : A267 - A267